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Abstract: One of the most important ideas ever produced by the application of materials science to 
the medical field is the notion of biomaterials. The nanostructured biomaterials play a crucial role 
in the development of new treatment strategies including not only the replacement of tissues and 
organs, but also repair and regeneration. They are designed to interact with damaged or injured 
tissues to induce regeneration, or as a forest for the production of laboratory tissues, so they must 
be micro-environmentally sensitive. The existing materials have many limitations, including 
impaired cell attachment, proliferation, and toxicity. Nanotechnology may open new avenues to 
bone tissue engineering by forming new assemblies similar in size and shape to the existing 
hierarchical bone structure. Organic and inorganic nanobiomaterials are increasingly used for bone 
tissue engineering applications because they may allow to overcome some of the current restrictions 
entailed by bone regeneration methods. This review covers the applications of different organic and 
inorganic nanobiomaterials in the field of hard tissue engineering. 
Keywords: nano-biomaterials; nanotechnology; scaffolds; hard tissue engineering 
 
1. Introduction 
Nanobiomaterials denote nanometer-sized materials whose structures and constituents have 
significant and novel characteristics with a strong impact on healing and medicine [1,2]. They include 
metals, ceramics, polymers, hydrogels, and novel self-assembled materials [3]. Rapid developments 
in nanotechnology not only led to create new materials and tools for biomedical applications, but also 
changed the way of using these materials in science and technology [4,5].  
Human bone is a dynamic tissue that can rebuild and remodel in the body throughout life [6]. 
The human bone is a hierarchical assembly of nano- to macro-scale organic and inorganic 
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components involved in transmitting physio-chemical and mechano-chemical cues [7,8]. The 
schematic of Figure 1 shows that normal human bone contains 30% organic collagen fibrils and 70% 
inorganic minerals [9–12], while 2% of the total volume is occupied by bone cells, osteoblasts, 
osteoclasts, lining cells, progenitor cells, and adipocytes [13,14]. Crystalline phases form 65% of the 
dry weight of the mineral matrix and most part of calcined fraction in calcium phosphate [15,16]. 
 
Figure 1. Composition of natural bone. 
The continuously growing population and the higher complexity of human interactions have 
generated new bone-related diseases (e.g., bone tumors, bone infections, and bone loss). This requires 
effective handling and treatment for bone regeneration [17,18]. Tissue engineering has revolutionized 
orthopedic and surgical studies, providing a new direction in the field based on nanoscale surface 
modification to simulate properties of extracellular matrix (ECM) and new foundations of structural 
variables of autologous tissue [19,20]. Tissue engineering is used to generate, restore, and/or replace 
tissues and organs by using biomaterials and helps to produce similar native tissue or organ [21].  
Nanotechnology solved many questions in tissue engineering by modifying regenerative 
strategies [22]. Biomedical applications of nanotechnology became a hot subject because different 
nanomaterials are utilized for the synthesis of scaffolds or implants [23,24]. These nanomaterials may 
be metallic [25], ceramic, or polymeric [26] with different structural forms such as tubes, rods, fibers, 
and spheres [27]. Various properties of materials such as physiochemical, electrical, mechanical, 
optical, catalytic, and magnetic properties can be improved at the nanoscale [28] and tailored to 
specific applications. Nanomaterials synthesized through top-down or bottom-up approaches [29] 
(Figure 2) have outstanding properties, which are used for biomedical applications particularly in 
tissue engineering [22].  
Nanomaterials 2020, 10, 2019 3 of 60 
 
 
Figure 2. Design of bioactive materials based on top-down and bottom-up approaches. 
Existing biomaterials often do not integrate with host tissue completely. This may cause 
infection and foreign body reactions that lead to implant failure [30]. Indeed, nanostructured 
biomaterials imitate the natural bone's extracellular matrix (ECM), producing an artificial 
microenvironment that promotes cell adhesion, proliferation and differentiation [31]. The specific 
biological, morphological, and biochemical properties of nanobiomaterials attract researchers to use 
them for the hard tissue engineering [32]. Nanostructured biomaterials can be used to fabricate high-
performance scaffolds or implants with tailored physical, chemical, and biological properties. Several 
natural and synthetic nanostructured biomaterials are now available for the fabrication of scaffolds 
with decent bioactivity [33].  
This survey article presents the most relevant applications of nanobiomaterials to bone tissue 
engineering, trying to highlight how organic and inorganic nanobiomaterials can deal with the above 
mentioned requirements on bone regeneration and the multiple challenges entailed by such a 
complicated subject. A broad overview of the various types of nanobiomaterials and their 
applications in the field of hard tissue engineering is provided. 
Besides the introductory articles mentioned above and other general articles on topics related to 
nanomaterials and the different contexts where they operate, the present survey covers some 550 
technical papers focusing on types, fabrication, and applications of nanobiomaterials. These articles 
have been selected using three widely used academic search engines: Scopus, Web of Science, and 
Google Scholar. For that purpose, keywords such as “tissue engineering”, “bone tissue engineering”, 
“tissue regeneration”, “scaffolds”, “nanomaterials”, and “nanobiomaterials” as well as their 
combinations have been used as input for the search process. High priority is given to peer-reviewed 
journal articles with respect to book chapters and conference proceedings, which count for some 10 
papers, less than 1.75% of the total number of surveyed articles. More detailed statistics on the articles 
surveyed for each topic will be reported at the end of the corresponding subsections. 
The paper is structured as follows. Sections 2 and 3 describe the various types of organic and 
inorganic nanobiomaterials and their applications in bone tissue engineering/regenerative medicines, 
drug/gene delivery, anti-infection properties, coatings, scaffold fabrication, and cancer therapy; 
generalizing conclusions are given at the end of each section. The conclusion section summarizes the 
main findings of this survey. 
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2. Nanobiomaterials 
Nanobiomaterials cover a wide variety of biomaterials including natural and artificial materials, 
used for various applications in tissue engineering [34–36]. These materials can be classified into two 
categories, i.e., organic nanobiomaterials and inorganic nanobiomaterials, where the former is 
characterized by the presence of carbon-containing constituents. Organic–inorganic hybrids are 
much more effective biomaterials than pure polymers, bioglasses, metals, alloys, and ceramics [37] 
as they try to combine best properties of constituents following the general concept of composite 
material. Section 2.1 will review the different types of organic nanobiomaterials, while Section 2.2 
will review the different types of inorganic nanobiomaterials. 
2.1. Organic Nanobiomaterials 
Nanostructured materials have characteristics like biocompatibility, nontoxicity, and non-
carcinogenicity. When used for replacement or restoration of body tissue, they are regarded as 
organic nanobiomaterials [38]. Several research groups have shifted their attention from metallic to 
organic nanomaterials, such as lipids, liposomes, dendrimers, and polymers including chitosan, 
gelatin, collagen, or other biodegradable polymers [39]. Organic materials are combinations of a few 
of the lightest elements, particularly hydrogen, nitrogen and oxygen, and carbon-containing chemical 
compounds located within living organisms [40]. Proteins, nucleic acids, lipids, and carbohydrates 
(the polysaccharides) are the basic types of organic materials [41]. 
Table 1 presents a general classification of organic nanobiomaterials and summarizes 
representative applications of each material in tissue engineering. The following subsections present 
a general description of each nanomaterial type listed in Table 1 and a detailed literature survey on 
the corresponding developments for tissue engineering. 
Table 1. Types of organic nanobiomaterials with their applications. 
Types of Nanomaterials Size (nm) Applications References 
Lipid <100 
Nanocarriers for anticancer 
drug doxorubicin 
Osteoblastic bone formation 
Osteoporosis treatment 
[42–45] 
Liposome >25 
High encapsulation of hydrophilic 
drug (drug delivery) 
Growth factor delivery 
Therapeutic gene delivery 
Used as a template 
[46–48] 
Dendrimers <10 Multidrug delivery system [46,49,50] 
Chitosan 20–200 
Nano/microparticles or fiber-based scaffolds 
Drug delivery 
Support chondrocyte adhesion 
Implant coating 
[51–55] 
Collagen  
Drug Delivery 
Scaffolds 
[56] 
Gelatin <200 
Bone scaffold systems formation 
Drug-loaded gelatin nanoparticles (DGNPs) 
Promote cell growth 
[24,57,58] 
Poly(lactic-co-glycolic acid) PLGA 100–250 
Drug delivery 
Scaffold system 
Nanostructured Film 
Enhanced cell attachment and growth 
[59–62] 
Carbon Nanotubes 20–100 
Drug delivery 
Biosensing 
Mechanically improved scaffold fabrication 
Enhanced rat brain neuron response 
[63–66] 
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2.1.1. Lipids 
Lipids are small hydrophobic or amphiphilic molecules [67]. They can be classified as fatty lipids 
of acylglycerol, phospholipids such as glycerides, seduction lipids, sterols, demonstrations of lipids 
played, lipids, and polylactide Kane [68]. Lipids are essential agents for the physiological and 
pathophysiological functioning of cells [69]. Generally, 10–1000 nm sized spherical lipid 
nanoparticles are synthesized [70]. All organisms consist of lipids as basic components, among other 
ingredients. The use of these lipids in pharmaceutical and biomedical fields can solve the problem of 
biocompatibility and biodegradation [71]. Besides liposomes (lipids arranged in the formation), other 
unique structures (e.g., hexagonal, spongy, solid structure, etc.) resulting from lipid polymorphisms 
also are available [72,73]. The latter have better stability and production efficiency than liposomes 
[48]. Lipid nanocarriers are better than polymeric nanoparticles (NPs) in terms of biocompatibility 
and lower toxicity, production cost and scalability, and encapsulation efficiency of highly lipophilic 
actives [74,75]. Lipid nanocarriers such as solid lipid nanoparticles (SLN) [76], nanostructured lipid 
carriers (NLC) [77], lipid nanocapsules (LNC) [78], and drug–lipid conjugates [79] are used for 
various administration routes (i.e., parenteral, oral, and topical ones) [80]. Lipid polymer hybrid 
nanoparticles (LPHNs) can also be used in the area of bioimaging agents for medicinal diagnostics as 
delivery vehicles like iron oxide, quantum dots (QDs) fluorescent dyes, and inorganic nanocrystals 
[81]. 
2.1.2. Liposomes  
Liposomes were discovered in the mid-1960s by A. D. Bangham [82]. The vesicle of the liposome 
is easily fabricated in a laboratory and made of one or more phospholipid bilayers [83] (Figure 3). 
These are self-assembled versatile particles with diameters ranging from nanometer to micrometer 
scale [84]. Resembling lipid cell membranes, the nature of phospholipid depends on the length of 
fatty acid chains [48]. They have the ability to encapsulate and carry hydrophobic aqueous agents 
[82]. They exhibit many advantages over other carrier systems [85,86].  
Bone morphogenetic protein-2 (BMP-2) is one of the most potent proteins in bone regeneration 
[87]. For this reason, encapsulation of BMP-2 in nanomaterials has attracted great interest. BMP-2-
loaded liposomal-based scaffolds may possess better osteoinductivity and bone formation ability 
[88].  
Liposomes can carry drugs directly to the site of action and sustain their levels without causing 
toxicity for long periods [89]. By changing the composition of lipids, liposome properties can change. 
Some liposome preparations for anticancer drugs have successfully released on the market by 
acquiring FDA’s approval [83]. Gentamycin- and vancomycin-integrated liposome-loaded particles 
are employed for manufacturing of scaffolds [90]. The integration of bioactive aspirin into a liposome 
delivery system would have a beneficial impact on stem cell osteoblast differentiation [91]. The initial 
drug amount and the chemical and physical drug properties are considerable factors for the 
encapsulation efficiency [92]. DOXIL®, the first FDA-approved nanodrug, which consists of 
liposomes encapsulating doxorubicin, was prepared by this remote loading method [93]. This 
method can also be used for preparing liposomes encapsulating other drugs such as daunorubicin 
and vincristine [94]. Liposomal systems are highly used despite being the oldest of the non-viralgene-
delivery vehicles [95]. Scaffolds used as delivery vehicles for bioactive agents offer many advantages 
such as enhanced and extended gene expression, and the ability to control a localized delivery of 
cargo [96] (see Figures 3 and 4). 
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Figure 3. Fabrication of liposome loaded scaffold. 
 
Figure 4. Schematic depiction of the role of tissue-engineered scaffolds in gene delivery [96] (adapted 
with permission from Elsevier © 2020). 
2.1.3. Dendrimers 
Dendrimers are the newest class of highly-defined macromolecules, which differs from simple 
polymers by branching at each repeating unit [97]. Their step-by-step controlled synthesis is used 
worldwide for molecular chemistry, while their repeating structure made of monomers relate them 
to the world of polymers [98,99]. The repetitively branched nanometer-scale dimension of 
dendrimers is an ideal candidate for a variety of tissue engineering [100], molecular imaging [101], 
and drug delivery [102] applications. Dendrimers can be a main component of scaffolds mimicking 
cross-linkers, chemical surface modifiers, and charge modifiers, as well as natural extracellular 
matrices [103].  
The combination of dendrimers with other conventional structural polymers, such as proteins, 
carbohydrates and linear synthetic polymers, leads to obtain new physical, mechanical and 
biochemical properties of hybrid structures [100,104]. The center of dendrimer may be composed of 
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polypropylimine (PPI), di-aminobutyl (DAB), polyamidoamine (PAMAM), and ethylenediamine 
(EDA), along with various surface residues such as amine, carboxyl, and alcoholic groups [105]. A 
dendrimer can be synthesized for particular use in different parts with controlled properties like 
solubility and thermal stability [106].  
Dendrimer–drug conjugation is a better approach to the encapsulation of cytotoxic 
pharmaceuticals. In this way, numerous cytotoxic and anticancer drugs, and targeted individuals 
such as monoclonal antibodies, peptides, and folic acid, can be conjugated to a single dendrimer 
molecule [107]. The drug is covalently conjugated to the dendrimer rather than complexed (Figure 5) 
[108] and these conjugates are relatively more stable. 
Dendrimers are a good choice for hydrophobic moieties and poorly water-soluble drugs [109]. 
PAMAM dendrimer/DNA complexes were employed to encapsulate functional fast biodegradable 
polymer films used for substrate-mediated gene delivery [110].  
 
Figure 5. Structure of a typical dendrimer–drug conjugate (Reused with permission from Elsevier [108].) 
The physicochemical characteristics, such as solubility and pharmacokinetics, of dendrimers are 
better than those of linear polymers. Therefore, dendrimers are ideal candidates for incorporation 
into scaffolds used for tissue engineering applications [111,112]. A few scaffolds were fabricated with 
dendrimers such as poly(caprolactone) chains conjugated to a poly(L-lysine) dendritic core to 
fabricate an HA-composite [113], linear PCL/n-HA hybrids [114], N-hydroxy succinimide/1-ethyl-3-
(3-dimethyl aminopropyl) carbodiimide (NHS/EDC) cross-linked scaffold [115], and dexamethasone 
carboxymethyl chitosan/PAMAM [116] for in vitro bone regeneration. 
2.1.4. Polymeric Nanomaterials 
Polymeric nanoparticles of size range 10 nm to 1 μm are the most advanced noninvasive 
approaches to tissue engineering and drug delivery applications [117]. They are comprised of 
repeating units of chain-like macromolecules with multiple structures and compositions [118]. In 
general, polymeric nanoparticles can be used for different applications by changing the 
physicochemical properties of nanoparticles. Polymers are differently processed to produce 
nanofibers [119], spherical nanoparticles [120] and polymeric micelles [121] for specific applications.  
There are several techniques to synthesize polymer-based nanoparticles, applied in tissue 
engineering [122]. Gelation [123], emulsion–solvent evaporation [124], nanoprecipitation [125], 
salting-out [122], and desolvation process [126] are generally preferred for natural polymers, like 
proteins and polysaccharides. Similar to other nanoparticle systems, polymer-based nanoparticles or 
nanocomposites can be functionalized to perform active targeting [127].  
Polymeric nanoparticles alter and may enhance the pharmacokinetic and pharmacodynamic 
properties used for various drug types because they show controlled and sustained release properties 
[128]. They offer a variety of benefits ranging from the administration of non-soluble drugs to 
protection of unstable compounds [129]. These nanoparticles can be loaded with therapeutic or 
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bioactive molecules (Figure 6) either by dispersion or adsorption within the polymer matrix, or 
encapsulation [130,131].  
Drug release may occur directly from nanoparticles through diffusion and polymeric 
nanoparticles may dissociate into monomers [132]. Polymers used for nanoparticle fabrication should 
be degradable via enzymatic or non-enzymatic routes under common metabolic pathways [133,134]. 
Drug-containing polymeric nanoparticles must be stable during migration to the plasma, that is, at 
almost neutral pH [135]. 
 
Figure 6. Bioactive/drug molecules loaded polymeric nanoparticles. 
Chitosan, collagen, gelatin, hyaluronic acid, alginate, and albumin are representative examples 
of natural biopolymers [136,137]. Polymeric nanoparticles are one of the fastest-growing platforms 
for the applications in tissue engineering because of their biocompatibility, biodegradability, low 
cytotoxicity, high permeation, ability to deliver poorly soluble drugs, and retaining bioactivity after 
degradation [117]. Some newly designed polymeric nanoparticles are sensitive to pH, temperature, 
oxidizing/reducing agents, and magnetic field which support a high efficiency and specificity for 
tissue engineering applications [138,139]. Due to good biocompatibility and adjustable chemical 
composition, and their ability to reorganize, polymeric nanoparticles are very promising as 
nanobiomaterials for the fabrication of scaffolds or bone substitutes [140]. Plasma protein-based 
nanoparticles have shown high biodegradability, bioavailability, long in vivo half-lives, and long 
shelf lives without any toxicity. Blood plasma is a complex mixture of 100,000 proteins, but only two 
of these proteins have been used in drug administration and tissue regeneration [141,142]. 
Chitosan 
Chitosan is a natural and nontoxic linear biopolymer synthesized from alkaline N-deacetylation 
of chitin [143]. It can be extracted from exoskeleton of crustacean shells (i.e., crabs and shrimps) some 
microbes, yeast, and fungi [144]. It has different molecular weights and is soluble in various organic 
solutions at pH 6.5 and below. The shape of the chitosan nanoparticles is affected by the degree of 
deacetylation [145,146]. The presence of amine and hydroxyl group leads the use of these compounds 
in many research areas [147,148]. Chitosan has outstanding biochemical properties, making it very 
attractive for applications in many areas including tissue engineering and/or regenerative medicine 
(Figure 7) [149]. Chitosan nanoparticles carry well therapeutic agents and biomolecules because of 
their high biocompatibility and biodegradability. Because of their small size, they can pass through 
biological barriers in vivo and deliver the drugs at the targeted site [150]. 
Nanomaterials 2020, 10, 2019 9 of 60 
 
 
Figure 7. Prospective applications of chitosan. 
Applications of Chitosan: Scaffolds prepared from chitosan and ceramics, especially 
hydroxyapatite, may have superior osteoconductive properties [151]. Bone morphogenetic protein-2 
(BMP-2)-loaded chitosan nanoparticles used for the coating of Ti implants were selected in order to 
examine bone regeneration in mice [55]. Chitosan and growth factor (BMP-7) were used to 
functionalize a thick electrospun poly(ε-caprolactone) nanofibrous implant (from 700 μm to 1 cm 
thick), which produced a fish scale-like chitosan/BMP-7 nano-reservoir. This nanofibrous implant 
mimicked the extracellular matrix and enabled in vitro colonization and bone regeneration [152]. 
There, the polycationic nature of chitosan entails an antimicrobial behavior at nanoscale [153]. Besides 
the orthodontic field, there are relevant applications of chitosan in skin healing, nerve regeneration, 
and oral mucosa [39]. Nanobioglass incorporated chitosan-gelatin scaffolds showed excellent 
cytocompatibility and ability to accelerate the crystallization of bone-like apatite in vitro [154,155]. 
The nanocomposite of chitosan/hydroxyapatite-zinc oxide (CTS/HAp-ZnO) supporting organically 
modified montmorillonite clay (OMMT) was synthesized and used for hard tissue engineering 
applications [156]. BMP-2 and BMP-7 loaded poly(3-hydroxybutyrate-co3-hydroxyvalerate) 
nanocapsules were used for the fabrication of chitosan-poly(ethylene oxide) scaffolds [157]. Mili et 
al. [158] used nerve growth factor (NGF) loaded chitosan nanoparticles for neural differentiation of 
canine mesenchymal stem cells. Freeze-dried nano-TiO2/chitosan scaffolds showed high 
biocompatibility and antibacterial effects [159]. Chitosan-poly(vinyl alcohol)-gum tragacanth 
(CS/PVA/GT) hybrid nanofibrous scaffolds showed 20MPa ultimate tensile strength and supported 
L929 fibroblast cells growth [160]. Collagen–chitosan–calcium phosphate microsphere scaffolds fused 
with glycolic acid did not show relevant differences in their degradation, cytocompatibility, porosity, 
and Young’s modulus [160,161]. 
Collagen 
The main constituents of living human bone are collagen type-1 (protein) and calcium phosphate 
or hydroxyapatite (mineral) [162]. Collagen is the major structural protein of the soft and hard tissues 
in living organisms [163]. It can have a significant role in preserving biological and structural integrity 
of extracellular matrix (ECM) [164]. It is a versatile material that is widely used in the biomedical field 
(Figure 8) due to advantages including high biocompatibility and biodegradability [165]. Collagen is 
mainly used as a carrier for drug delivery as well as osteogenic and bone filling material [166]. 
Collagen matrix was also used to deliver gene promoting bone synthesis [167]. Collagen with 
recombinant human bone morphogenetic protein-2 was used to monitor bone formation [168]. 
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Figure 8. Biomedical applications of collagen. 
Bone morphogenic protein (BMP)-loaded collagen activates osteoinduction in the host tissue 
[169]. Collagen-based nanospheres/nanoparticles can be used as a systematic delivery carrier for 
various therapeutic agents or biomolecules [166]. As collagen type-I and hydroxyapatite are a basic 
part of the bone, hydroxyapatite and collagen were used to fabricate scaffolds that enhance osteoblast 
differentiation and accelerate osteogenesis [170].  
Collagen-based biomaterials in various formats such as 3-D scaffolds have been employed for 
tissue engineering [171]. The combination of collagen with elastin was successfully fabricated and in 
vitro tests proved the adhesion and proliferation of cells without any cytotoxicity [172]. Collagen-
based inks were used for 3D bioprinting employed for tissue repairing and scaffold fabrication. The 
collagen-based ink was extruded with a temperature stage of −40 °C, followed by freeze-drying and 
cross-linking by using 1-ethyl-(3-3-dimethylaminopropyl) hydrochloride solution [173]. 
Gelatin 
Gelatin represents a derivative of collagen, extracted by collagen hydrolysis from the skin, 
bones, and/or connective tissues of animals. It is a cost effective, biocompatible, and biodegradable 
polymer, which supports cross-linking of functional groups. Gelatin is a versatile polymer that is 
known for his wealth merits [174]. Pharmaceutical or medical grade gelatin has fragility and 
transparency for tablet coatings, suspensions, capsule formulations, and nano-formulations (Figure 
9).  
Nanomaterials 2020, 10, 2019 11 of 60 
 
 
Figure 9. Biomedical and pharmaceutical uses of gelatin. 
Because of their great biocompatibility, the injected gelatin-loaded nanoparticles have been 
reported in the skeletal system [24,175,176]. It is a polyampholyte at pH 9 (gelatin A) and pH 5 (gelatin 
B). Gelatin nanoparticles are used as a biomaterial for the delivery of biomolecules and therapeutic 
agents [177]. However, digestive process of gelatin showed low antigenicity, with the formation of 
harmless metabolic products. In order to prevent infectious disease transmission, genetic engineering 
approaches were used for the production of human recombinant gelatin [178,179].  
At the nanoscale, gelatin shows high biocompatibility, biodegradability, and low 
immunogenicity [180]. The presence of a higher number of functional groups on polymer backbone 
helps with crosslinking and chemical modification [181]. The cross-linking is necessary to stabilize 
the macromolecular structure of gelatin is not stable at normal body temperature due to the low 
melting temperature [182,183].  
Gelatin methacryloyl (GelMA) hybrid hydrogel demonstrated a wide range of tissue 
engineering applications. When exposed to light irradiation, GelMA scaffolds convert into hydrogels 
with tunable mechanical properties [184]. Gelatin enables therapeutic cell adhesion without 
comprising cell phenotypes [185]. Porous HA-gelatin microparticles (1 to 100 μm) support human 
osteoblast-like Saos-2 cells growth and cell delivery [186]. A mechanically strong gelatin–silk 
hydrogel composite was prepared by direct blending of gelatin with amorphous Bombyxmori silk 
fibroin (SF) [187]. Gelatin coated polyamide (PA) scaffold showed good biomechanical, cell 
attachment, and wound healing characteristics while being transplanted to nude rats [188]. 
Poly(lactide-co-glycolide) (PLGA)–gelatin fibrous scaffolds possess the highest Young’s modulus 
(770 ± 131 kPa) and tensile strength (130 ± 7 kPa) [189]. Methacrylamide-modified gelatin (GelMOD) 
3D CAD scaffolds showed excellent stability in culture medium and support porcine mesenchymal 
stem cell adhesion and subsequent proliferation [190]. 
Gelatin-based microcarriers used embryonic stem cell delivery for the applications in tissue 
engineering [191]. The magnetic nanoparticles were assembled with magnetic gelatin membranes to 
produce 3D multilayered scaffolds (Figure 10), which are used for controlled distribution of 
magnetically labeled stem cells [192].  
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Figure 10. (A) Fabrication of a multilayered magnetic gelatin scaffold. (B) Magnetic gelatin 
membranes with increasing MNPs concentration from left to right as well as a representation of the 
properties of the magnetic gradient. (Adapted with permission from © 2020 American Chemical 
Society [192]). 
Poly (Lactic-co-glycolic) acid (PLGA) 
PLGA is considered as one of the most efficient tissue engineering materials due to its (i) high 
biocompatibility, (ii) biodegradability, (iii) potential to interact with biological materials, and (iv) 
clinical use approved by FDA [193]. Biodegradable biomolecule-loaded PLGA nanoparticles can be 
used for the preparation of a drug delivery system, which can be further utilized in scaffold 
fabrications [194–196]. These nanoparticles may increase the mechanical properties of the scaffolds 
but decrease swelling behavior without changing the morphology of the scaffold [197]. Afterward, 
this system is effective to prepare a controlled release platform for model drugs that favors the bio-
distribution and development of clinically relevant therapies [198]. Different methods such as gas 
foaming [199], porogen leaching [200], solid freedom fabrication [201], and phase separation [202] 
can be used for PLGA scaffolds fabrication. 
2.1.5. Carbon Nanostructures 
Carbon nanomaterials are great candidate materials for bone tissue engineering due to their 
conductivity, lightweight, stability and strength [203]. Nanostructures such as fullerenes, carbon 
nanotubes, carbon nanofibers, and graphene are the most common structures (Figure 11) [204,205]. 
 
Figure 11. Structure of various allotropes of carbon (adapted with permission from Royal Society of 
Chemistry [205]). In the figure, “BCB” stands for “benzocyclobutene”. 
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Han et al. [205] pointed out that carbon is biocompatible and can be used in many clinical 
applications, such as prosthetic heart valves. However, a pure form of carbon nanomaterials cannot 
be used as a substrate for bone tissue [206]. Therefore, carbon-based materials are used in combined 
form to fabricate scaffolds [207]. Carbon nanostructures doped or reinforced compositions became 
more popular due to their high performance and compatibility with bone tissues [203]. 
Carbon nanofibers (CNF) are cylindrical or conical structures of various diameters and lengths. 
The interior structure of the CNF contains an improved layout of graphene sheets. Graphene is a 
single-layer two-dimensional material composed of long-edged reactive carbon atoms. Graphene 
leaves are characterized by stable dispersion and orientation of nanofillers [208–210]. 
Carbon nanotubes (CNT) enhance mechanical and electrical properties, which helps to generate 
innovative products. CNTs are one of the ideal and favorable materials used for designing novel 
polymer composites [211]. Many authors focused on the progress of composite materials fabrication-
integrating CNTs to enhance its applications in biomedical field [212–216].  
Nanodiamonds (4–10 nm) are typically different from other nanostructures as they are sp3 
hybridized [203]. They show admirable protein binding ability and can be used as a carrier for some 
biomolecules such as BMP-2 [217]. The carbon nanotube/gold hybrids are employed commonly for 
the delivery of the anticancer drug doxorubicin hydrochloride into A549 lung cancer cell line [218].  
Nanoscaffolds can be produced by electrospinning poly(ε-caprolactone) (PCL) and different 
types of carbon nanomaterials such as carbon nanotubes, graphene, and fullerene [219]. Mesoporous 
silica (mSiO2) decorated carbon nanotubes (CNTs) hybrid composite were used for the simultaneous 
applications of gentamicin and protein cytochrome C delivery and imaging [220]. Single-walled 
carbon nano-horns encapsulated with positively charged lipids complex were used for targeted drug 
and protein delivery [221]. 
2.1.6. Summary and Statistical Analysis of the Survey on Organic Nanobiomaterials  
The survey on organic nanobiomaterials presented in Section 2.1 regarded some 200 articles. 
Polymeric nanomaterials, carbon nanostructures, and nanocomposite materials are the most widely 
investigated subject (60.8% of the studies), followed by dendrimers (21.1%) and lipids/liposomes 
(18.1%). While dendrimers and lipid/liposomes are mainly utilized as nanocarriers, the other 
nanomaterials cover a much broader spectrum of applications. The development of new 
nanomaterials (especially carbon nanomaterials or materials including natural bone constituents 
such as, for example, collagen) that can improve tissue regeneration, cell growth, and drug/protein 
delivery currently represents the main research area in the field of organic nanobiomaterials with a 
strong tendency to design hybrid materials and improve fabrication techniques of the resulting 
nanocomposite materials/scaffolds/structures. Such a trend has become very clear in the last 5–6 
years. However, much work remains to be done in order to fully understand interactions between 
different phases of nanocomposite materials and cell/tissues to be repaired/treated. Another 
important issue strictly related to the above mentioned one is how to “optimize” the composition of 
the nanocomposite for the specific purposes on which the material itself is designed. 
2.2. Inorganic Nanobiomaterials 
Inorganic biomaterials are those lacking carbon element and they are widely employed for in 
vivo and in vitro biomedical research [222]. These crystalline or glass structured nanomaterials are 
used to replace or restore a body tissue [36]. The main applications of inorganic biomaterials, 
including bioceramics and bioglasses, are for orthopedics and dentistry. Modifications in 
composition and fabrication techniques may produce a range of biocompatible materials such as 
bioceramics [223]. Natural bone also includes inorganic materials like calcium (Ca) and phosphorus 
(P) in the form of hydroxyapatite (HA) crystals, as well as carbonate (CO32−), potassium (K), fluoride 
(F), chlorine (Cl), sodium (Na), magnesium (Mg), and some trace elements including copper (Cu), 
zinc (Zn), strontium (Sr), iron (Fe), and silicon (Si) [224]. Therefore, it is very logical to investigate on 
nanomaterials based on these inorganic constituents. 
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Table 2 presents a general classification of inorganic nanobiomaterials and summarizes 
representative applications of each material in tissue engineering. The following subsections present 
a general description of each nanomaterial type listed in Table 2 and a detailed literature survey on 
the corresponding developments for tissue engineering. 
Table 2. Types of inorganic nanomaterials with their applications. 
Types of Nanomaterials Size (nm) Applications Reference 
Nano Silica 10–100 
Composite-based scaffold 
Bio-imaging 
Drug delivery 
Enhanced osteogenic differentiation 
[225–227] 
Gold nanostructured materials 5–50 
Bioinorganic hybrid nanostructures 
Thin film scaffold 
Bio-imaging 
[228–230] 
Magnetic nanomaterials and nanoparticles 10 
Drug and gene delivery 
Improved cell adhesion 
Cell tracking  
[21,231,232] 
Bioactive Glasses 20–500 
Improved scaffolds performance 
Drug and gene delivery  
[233,234] 
Silver nanoparticles 1–100 
Tissue repair and regeneration 
Antibacterial action 
[235–237] 
Nanostructured Titanium <300 
Nano tubular anodized titanium 
Improved mechanical properties 
Enhanced chondrocyte adhesion 
Support osteoblast adhesion and proliferation 
Orthopedic coating 
[238–243] 
Hydroxyapatite 
20–80 
~200–500 
Enhanced osteoblast functioning 
Increase bone apatite formation 
[244,245] 
Zirconia nanoparticles <100 
Enhanced osteointegration 
Antibacterial implants formation  
[246,247] 
Alumina nanoparticles <80 
Enhanced bone cells adhesion and proliferation 
Calcium phase deposition 
[245,248] 
Copper nanoparticles <100 Antimicrobial implant fabrication [25] 
2.2.1. Nano Silica 
A huge amount of investigations on biomedical applications of silica nanostructures have been 
carried out in the past decade [249]. The ability to synthesize uniform, porous and dispersible 
nanoparticles, together with the fact that particles’ size and shape can be easily controlled [226], 
certainly favored the variety of applications of silica in tissue engineering [250]. Furthermore, as silica 
is biocompatible and chemically stable [251,252], it has been used also for biomedical imaging and 
medication administration [225], either itself or as a coating of other compounds [251]. 
Mesoporous silica nanoparticles (MSNPs) have been used as a drug delivery vehicle [253] and 
to improve mechanical properties of biological materials. It was noted their use as well as for 
sustained and prolonged release or administration of intracellular genes in bone tissue engineering 
[226]. MSNPs work as efficient biocompatible nanocarriers due to (i) high visibility, (ii) dispersibility, 
(iii) binding capability to a target tissue, (iv) ability to load and deliver large concentrations of cargos, 
and (v) triggered or controlled release of cargos [250]. The functioning of MSNPs can be tailored by 
modifying the silanol group present within the pore interiors and on the outer surface. These positive 
chemical moieties are adsorbed by negatively charged SiO– groups at neutral pH, through 
electrostatic interactions (Figure 12).  
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Figure 12. Schematic of a multifunctional mesoporous silica nanoparticle showing possible core/shell 
design, surface modifications, and multiple types of cargos. (Adapted with permission from © 2020 
American Chemical Society [250]). 
Anitha et al. [254] reported a composite matrix containing crystalline rod-shaped core with 
uniform amorphous silica sheath (Si–n HA), which showed good biocompatibility, osteogenic 
differentiation, vascularization, and bone regeneration potential. Silicate containing hydroxyapatite 
stimulates cell viability of human mesenchymal stem cells for extended proliferation [255]. Zhou et 
al. [256] synthesized PLGA–SBA15 composite membranes with different silica contents by 
electrospinning method; these membranes showed better osteogenic initiation then the pure PLGA 
membranes. Ding et al. [257] successfully fabricated levofloxacin (LFX)-loaded 
polyhydroxybutyrate/poly(ε-caprolactone) (PHB/PCL) and PHB/PCL/sol–gel-derived silica (SGS) 
scaffolds, which support the growth of MG-63 osteoblasts. A microfluidic device was used to 
generate photo-cross-linkable gelatin microgels (GelMA), coupled with providing a protective silica 
hydrogel layer for applications in injectable tissue constructs [258]. Dexamethasone (DEX)-loaded 
aminated mesoporous silica nanoparticles (MSNs-NH2) were prepared via electrophoretic 
deposition (EPD) and successfully incorporated within poly(l-lactic acid)/poly(ε-caprolactone) 
(PLLA/PCL) matrix to fabricate composite nanofibrous scaffolds for bone tissue engineering 
applications [259].  
2.2.2. Nano Bioglass 
Bioglasses (BG) have been intensively investigated as biomaterials since their discovery in 1969 
and first developments in the 1970s made by L. Hench [260]. Compared to common glass, bioglass 
contains less silica and higher amounts of calcium and phosphorous. As a biomaterial for tissue 
engineering, bioglass is applied independently or in combination with a number of polymers [261] 
(Figure 13). BG can arouse fibroblasts with higher bioactivity by accelerating bioactive growth factors 
and proteins as compared to untreated fibroblasts [262].  
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Figure 13. Biomedical applications of hydroxyapatite and glass ceramics. 
BG degrade slowly when implanted into the targeted patient’s site and release ions, which favors 
the biosynthesis of hydroxyapatite [263]. The silica-rich surface of bioglass promotes the exchange of 
Ca2+ and PO43− with physiological fluid, which leads to the generation of a Ca–P layer [264,265]. This 
biodegradation may be enhanced by the presence of a SiO2 network, which forms non-bridging 
silicon-oxygen bonds [266]; the low connectivity of the SiO2 network enhances dissolution of bioglass 
while the presence of Na and Ca forms Si–O–Si bonds and reduces dissolution rate. Mesoporous BG 
can be fabricated using the sol-gel method, which can be a good carrier for targeted drug delivery 
[267]. The sol–gel method was also used by Kumar et al. [268] to develop bioglass nanoparticles with 
a higher content of silica, which are suited for bone tissue applications. 
Bioglass nanoparticles show high biocompatibility and surface area, which can enhance in vitro 
osteoconductivity as compared to layer and microsized particles of bioglass [269]. The size of the 
particles can be modified by changing the synthesis parameters and techniques. However, because 
of its brittleness, the glass alone cannot be used to heal large bone defects [270]. In order to solve this 
issue, Bioglass 45S5 was used with poly(D,L-lactide) (PDLLA), a biodegradable polymer, to form a 
composite scaffold with enhanced biomechanical characteristics [271]. The early failure of a bioglass 
composite at the interface occurs because of nonuniform mechanical strength, phase separation, 
nonhomogeneous mixture, and different degradation properties of two compounds. A hybrid 
composite of poly(methyl methacrylate) (PMMA) and bioactive glass was manufactured via the sol-
gel method (Figure 14) to enhance physicochemical and mechanical properties [272]. 
 
Figure 14. Schematic procedure for the fabrication of a PMMA-bioglass class II hybrid (Adapted with 
permission from © 2020 American Chemical Society [272]). 
Nanomaterials 2020, 10, 2019 17 of 60 
 
An elastin-like polypeptidic and bioglass (ELP/BG) hydrogel was also fabricated that is 
mechanically robust, injectable, and self-healable. This ELP/BG biocomposite can be useful for drug 
delivery and tissue engineering purposes [273]. A 3D construct of type-I collagen and 45S5 Bioglass 
meets the basic requirements of a scaffold including biocompatibility, osteoconductivity, 
osteoinductivity, and biodegradability [274]. Bioglass nanoparticles were also used with bacterially 
derived poly(3-hydroxybutyrate) to fabricate bioactive composite film using a fermentation 
technique [275]. Different glass modifiers (Mg2+, Ca2+, and Sr2+) were used to prepare borosilicate 
bioactive glasses through a melt-quenching technique which showed good antibacterial properties 
[276]. Poly(propylene fumarate) (PPF) was used to functionalize bioglass particles that enhance the 
bioactivity and cell adhesion, proliferation, and bone regeneration [277]. 
2.2.3. Nano Hydroxyapatite 
Hydroxyapatite (Ca10(PO4)6(OH)2) is a significant natural mineral constituent of bones (70% wt.) 
and teeth (96% wt.) [278,279]. Synthetic HA is a biocompatible ceramic material, used for biomedical 
applications (Figure 13) because it may replicate the behavior of mineral part of the bone [280,281]. It 
shows outstanding biocompatibility with bones, teeth, skin, and muscles, both in vitro and in vivo 
[282,283]. The stoichiometric molar ratio Ca/P in synthetic HA of 1.67 is not the actual ratio in the 
hydroxyapatite of normal bones, because of the presence of other elements such as C, N, Fe, Mg, and 
Na [284]. Hydroxyapatite (HA) can be easily synthesized by using different methods such as 
hydrothermal, sol–gel, and co-precipitation methods [285]. The comparison of mineral compositions 
of hydroxyapatite, bone and teeth is shown in Table 3 [286,287].  
Table 3. Mineral composition of hydroxyapatite, bone, and teeth. 
Types Ca P Ca/P Total Inorganic (%) Total Organic (%) Water (%) 
HA 39.6 18.5 1.67 100 - - 
Dentine 35.1 16.9 1.61 70 20 10 
Bone 34.8 15.2 1.71 65 25 10 
Enamel 36.5 17.1 1.63 97 1.5 1.5 
HA shows such excellent biocompatibility, bio-inertia and bioactivity without toxicity, 
immunogenicity [288,289]. It has a good ability to make bonds with bone directly and it is primarily 
used in therapeutic applications such as implants and fillers for bones and teeth in different forms 
[290]. To overcome the low mechanical strength of hydroxyapatite scaffolds, a large number of 
natural and synthetic polymers were combined with HA such as collagen, polyethylene, polylactic 
acid, alginates, poly(methyl methacrylate), and polycaprolactone [136]. 
Woodard et al. [291] compared the activity of nano- and microsized ceramic materials in the 
body. Their studies demonstrated a substantial increase in osteoblast adhesion and protein 
adsorption in nanomaterials. The major components of the inorganic nanostructure can have a higher 
biological activity than micro-components [245]. Polydopamine (pDA)-templated hydroxyapatite 
(tHA) was introduced into polycaprolactone (PCL) matrix to make bioactive tHA/PCL composite 
based fibrous scaffold; in vitro and in vivo investigations (Figure 15) showed a favorable 
cytocompatibility at a given concentration of tHA (0–10% wt.) [292].  
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Figure 15. Schematic illustration of preparation and evaluation of tHA/PCL composite nanofibers. 
(Adapted with permission from © 2020 American Chemical Society [292].) 
A new type of scaffold with bamboo fiber (5%) incorporated nano-hydroxyapatite/poly(lactic-
co-glycolic) (30%) was fabricated via freeze-drying; bamboo fibers improved biomechanical 
properties of n-HA/PLGA composite scaffolds thus developing a superior potential for bone tissue 
engineering [293]. Sol–gel synthesized hydroxyapatite–TiO2-based nanocomposites synthesized in 
supercritical CO2 have better Young’s and flexural moduli than PCL/HAp composites [294]. A set of 
techniques including molding/particle leaching and plasma-treated surface deposition were used to 
fabricate bilayered PLGA/PLGA-HAp composite scaffold [295]; the in vivo rat model experiment 
proved that the new composite is suitable for osteochondral tissue engineering applications. 
Electrospinning mediated poly(ε-caprolactone)−poly(ethylene glycol)−poly(ε-caprolactone) (PCL–
PEG–PCL, PCEC) and nano-hydroxyapatite (n-HA) composite scaffolds showed good 
biocompatibility and nontoxicity, [296]. Hydroxyapatite/Na(Y/Gd)F4:Yb3+,Er3+ composite fibers [297], 
and gadolinium-doped mesoporous strontium hydroxyapatite nanorods [298] were successfully 
used in drug storage/release applications. 
2.2.4. Silver Nanoparticles 
Silver proved its bactericidal activities against many bacteria since 1000 B.C. Now silver is used 
as an antiseptic, antibacterial, and antitumor agent [299]. Because of their strong antibacterial activity 
against both Gram-positive and Gram-negative bacterial strains, silver nanoparticles were widely 
used for fabricating antibacterial nanocomposite-based scaffolds and coated implants [235,237]. 
Furthermore, silver may be combined with different materials such as CNT [300], chitosan, HA [301], 
and manganite [302] to get a specific function. Ag-doped or coated implants allow reducing the 
number of bacterial infections without interfering with bone cell growth in the body (Figure 16, [303]). 
The antimicrobial activity of Ag has been reported against Escherichia coli [304], Candida albicans [11], 
Vibrio cholera [305], and Staphylococcus aureus [306].  
In addition to antibacterial activity, Ag nanoparticles promote wound healing, reduce scar 
formation, and reduce inflammation [307]. Silver nanoparticles have many applications as 
antimicrobial agents when combined with different biological substances [308]. A micrometer-sized 
surface-enhanced Raman spectroscopy (SERS) substrate, core–shell microparticles composed of solid 
carbonate core coated with silver nanoparticles, and polyhedral multishell fullerene-like structure 
were developed for biomedical applications [309]. Soft poly(vinyl alcohol) (PVA) hydrogel films 
containing silver particles prepared on solid biodegradable poly(l-lactic acid) (PLLA) exhibit both 
Nanomaterials 2020, 10, 2019 19 of 60 
 
antibacterial and reduced cell adhesion properties [310]. Biocompatible maleimide-coated silver 
nanoparticles (Ag NPs) can be used as co-cross-linkers for the preparation of a nanocomposite 
gelatin-based hydrogel. Covalently bound Ag nanoparticles support swelling and drug release 
properties of composite hydrogel without producing toxicity [311]. In situ fabricated Ag NPs (4-19 
nm) and immobilized on titanium by using a plasma immersion ion implantation process motivated 
osteoblast differentiation in rat bone marrow stem cells (BMSCs) [312]. Patrascu et al. [313] fabricated 
collagen/hydroxyapatite-silver nanoparticles (COLL/HA-Ag)-based antiseptic composite for 
biomedical applications.  
 
Figure 16. Schematic diagram representing mechanisms of action of Ag nanoparticles for antibacterial 
action (adapted with permission from Elsevier © 2020 [303]). (A) AgNP diffusion and uptake into the 
bacterial cell. (B) Destabilization of ribosomes. (C) Enzyme interaction. (D) Interruption of electron 
transfer chain. (E) Reactive oxygen species (ROS). (F) DNA damage. (G) Cell death. 
2.2.5. Gold Nanoparticles 
Gold nanoparticles (GNPs) are defined as a colloid of nanometer-sized particles with better 
properties than bulk gold. They are produced in different shapes such as spheres [314], rods [315], 
star-like [316], and cages [317]. GNPs possess unique characteristics, such as easy-to-control, 
nanoscale size, easy preparation, high surface area, easy functionalization, and excellent 
biocompatibility, that make them highly suited for many tissue engineering and more in general for 
biotechnology applications [318,319]. GNPs are definitely superior over other types of nanoparticles 
in terms of low toxicity and colloidal stability. Furthermore, they present an outstanding 
physicochemical behavior, which is related to local plasmon resonance phenomena. 
Gold nanoparticles were utilized for biosensing [320], bioimaging [321–323], cancer therapy 
[324], gene delivery to enhance osteogenic differentiation [325], and photo-thermal therapy 
[229,314,316,323]. Gold nanoparticles were also combined with other materials such as silica (to 
produce core and shell nanoparticles) [318,323] as well as natural polymers (to improve mechanical 
properties) and synthetic polymers (to enhance biocompatibility) [318].  
Due to their excellent biocompatibility and chemical inertness, gold nanoparticles became the 
ideal choice for the preparation of scaffolds in many cases [318]. The mission of GNPs in tissue 
engineering and regenerative medicine is to act as a multimodal tool in order to improve scaffold 
properties, cell differentiation and intracellular growth factor delivery (Figure 17), while monitoring 
cellular events in real-time [326]. 
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Figure 17. Scheme representing the importance of introducing GNPs in tissue engineering and the 
regenerative medicine (TERM) realm [326]. (Adapted with permission from Elsevier © 2020.) 
2.2.6. Titanium Dioxide 
Titanium is widely used in many surgical applications (e.g., prostheses and implants) because 
of its excellent biocompatibility, good mechanical properties, and lower mass density than steel [327]. 
The low density and high specific strength of titanium results in lightweight implants with good 
mechanical properties [238,239]. Furthermore, the smooth surface of Ti mesh prevents bacterial 
contamination instead of adsorbate materials. Therefore, titanium mesh provides an excellent 
solution to guide bone regeneration [243].  
Nanostructured TiO2 materials of various morphologies such as nanoparticles, nanorods, 
nanowires, nanotubes, and other hierarchical nanostructures can be produced using different 
techniques such as, for example, microwaves [328,329], hydrothermal/solvothermal processes 
[330,331], sol–gel [332,333], anode oxidation [334,335], chemical vapor deposition [336,337], 
sonochemical processes [338,339], and green synthesis [340–342].  
As can be seen from Figure 18, nanostructured TiO2 is a multifunctional material for a wide 
range of applications in engineering and biomedical areas. Interestingly, TiO2 nanoparticles represent 
a miniature of electrochemical cells capable of light-induced redox chemistry. This quality can be 
used for manipulating biomolecules and cell metabolic processes. TiO2 nanoparticles prove to have 
a higher affinity for binding proteins and other cellular components when used within cellular 
environment [343,344]. TiO2 nanoparticles can also be used to enhance photodynamic therapy (PDT) 
and sonodynamic therapy (SDT) [345]. 
Titanium nanotubes (TNTs) possess excellent biocompatibility and drug-releasing performance. 
Furthermore, they can be generated on the surface of the existing medical implants [346,347]. The 
physical adsorption of the drugs promotes the anti-inflammatory properties of the TNTs, and with 
improved osteoblast adhesion, the drug-eluting technique is extended [348].  
TiO2 based scaffolds are biocompatible, have good osteoconductive performance and 
antibacterial properties [349], and show high porosity, excellent interconnectivity, and sufficient 
mechanical strength [350,351]. Nanostructured TiO2 can be combined with several polymers 
including polylactic acid (PLA) [352]; poly(ether-ether ketone) (PEEK) [353]; poly(lactic-co-glycolic 
acid) (PLGA) [354]; and inorganic materials such as SiO2 [355], Al2O3 [356], bioglass [357], 
hydroxyapatite [358], graphene [359], and calcium phosphate [360]. 
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Figure 18. Schematic representation of the many fields of applications of nanostructuredTiO2. 
Nano-TiO2 surface coated implants can limit autoimmune reactions between the underlying 
bone tissue surfaces and the implant [361]. However, material deterioration or generation of chronic 
inflammation in the implanted tissues may reduce success rate [361,362]. Various TiO2 nanostructures 
were used for loading and eluting cefuroxime as an antibiotic on orthopedic implants [363]. 
2.2.7. Zirconia  
Zirconia was first recognized by M.H. Klaproth in 1789 and used as a pigment for ceramics for 
a long time [364]. Since the 1970s, zirconia received massive consideration as a biomedical material 
in association to its chemical and biological inertness [365]. Consequently, zirconia was also used to 
overcome the brittleness of alumina and the consequent failure of implants [366], and as a material 
for the repair and replacement of bones due to its unique biomechanical properties [367]. 
Investigations on zirconia biomaterials began in the 1960s. Classical orthopedics studied for 
many years have used zirconia in the area of hip replacement [368,369]. Zirconium oxide (zirconia) 
possesses improved mechanical properties and has become one of the most popular ceramic 
materials in the field of healthcare due to its high biocompatibility and low toxicity [364,370].  
Zirconia is one of the most useful structured ceramics because it provides high resistance to 
bending and fracture. However, zirconium oxide with a low fracture toughness due to the presence 
of alumina abrasive grains [371] also was introduced as an alternative to having excellent wear 
resistance due to the unwanted release of orthopedic alumina. Porous zirconia stents can be 
manufactured by cutting CAD/CAM blocks in the desired shape, and zirconia stents assembled with 
HA significantly increase the volume of new bone formation in vivo [372].  
While it might be concluded that zirconia has one of the best combinations of mechanical 
strength, fracture resistance, biocompatibility, and biological activity, its performance can be further 
enhanced via a proper modification of material’s surface or by combining the material with some 
other bioactive ceramics and glass [367]. In addition, as a result of the introduction of Zr into the Ca-
Si system, no toxicity was observed. Previous studies confirmed that the optimum content of 
zirconium and strontium increases the surface energy of the magnesium alloy and enhances the 
ability to stimulate bone formation around the implant [373,374]. Hydroxyapatite and fluorapatite 
slurry coated zirconia scaffolds induce osteoconductivity and enhance bonding strength up to 33 
MPa [375]. The dispersion of zirconia with alumina lead to produce ZrO2-toughened alumina (Al2O3), 
known as zirconia-toughened alumina (ZTA) [376].  
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Zirconia (ZrO2)/β-tricalcium phosphate (β-TCP) composite has shown excellent mechanical 
properties and supports osteoblast regeneration [377]. Silk fibroin-chitosan-zirconia (SF/CS/nano 
ZrO2) and chitin–chitosan/nano ZrO2 composites provide a suitable environment for cell infiltration 
and colonization [378,379]. Different temperature based hydroxyapatite-zirconium composites such 
as 873 K (HZ600), 923 K (HZ650), and 973 K (HZ700) demonstrated that osteoblast growth and 
mineralization were not influenced by any composite [380]. A new biphasic calcium phosphate (BCP) 
scaffold reinforced with zirconia (ZrO2) was fabricated through the fused deposition modeling (FDM) 
technique. The 90% BCP and 10% ZrO2 scaffold thus created had significantly better mechanical 
properties than 100% BCP and 0% ZrO2 scaffold [381]. 
ZrO2 nanoparticle (NP)-doped CTS–PVA–HAP composites (ZrCPH I–III) showed improvement 
in the tensile strength of ZrCPH I–III with respect to the CTS–PVA–HAP scaffold [382]. Sol–gel cum 
solvothermal derived mesoporous titanium zirconium (TiZr) oxide nanospheres were used for 
ibuprofen, dexamethasone, and erythromycin drugs loading and in vitro release studies [383]. The 
excellent biocompatibility of Zr makes it a good material for metal–organic frameworks (MOFs). 
Surface functionalization of Zr-fumarate MOF (Figure 19) was used for dichloroacetate (DCA) drug 
loading, which is more efficient at transporting the drug mimic calcein into HeLa cells [384]. 
 
Figure 19. Schematic showing the Zr-fumarate structure with preferred properties of a metal–organic 
framework (MOF)-based drug delivery device (adapted with permission from © 2020 American 
Chemical Society [384]). 
2.2.8. Alumina 
Since 1975, the bio-inertness of alumina has been confirmed. Alumina has very high hardness 
and resistance to abrasion on the Moh scale next to diamond [385]. In addition, the crystalline nature 
of alumina makes it insoluble at room temperature in regular chemical reagents [386]. Alumina has 
been used in many fabrications of artificial implants since it was inserted into an artificial femur head 
in the 1970s [387]. Pure and densified alumina, α-Al2O3 (corundum), was the first ceramic material 
used in the biomedical field for dental restorations, cochlear implants, and load-bearing hip 
prostheses [388]. As porous alumina does not degrade under in vitro and in vivo environments, it 
may be used for biosensing [389], good electrical insulation [390], and immune isolation [391].  
Properties such as abrasion resistance, power and chemical inertness favor the use of alumina in 
hard tissue engineering [392]. If the alumina is implanted in bone marrow, no toxic effects are 
generated in the surrounding tissue [393]. However, the high stiffness of alumina may lead to have a 
high elastic incompatibility between the biological tissue and the implant [394]. The tensile strength 
of alumina can be increased by reducing grain size and increasing its density [395]. In view of their 
Nanomaterials 2020, 10, 2019 23 of 60 
 
good mechanical behavior, alumina implants are characterized by long-time survival predictions 
[396].  
A significant feature in applications involving open and aligned porous structures, such as bone 
tissue scaffolds, catalysts, and membranes, is the anisotropic nature of porous alumina ceramics [397]. 
The α-alumina is the most stable oxide amongst transient and metastable types [398]. It should be 
noted that essential physico-chemical properties of alumina surface are significantly affected by the 
protein adsorption process. For example, the presence of liquid solutions nearby the implanted site 
can cause accelerated protein adsorption on the alumina’s surface [399]. Piconi et al. [394]] reported 
the in vitro biocompatibility of alumina with various cell lines such as fibroblasts and osteoblasts, 
and immunological cells with various cell environments. 
The particle size of alumina may affect biocompatibility, particularly when using nanoparticles 
because of their high surface/volume ratio [400]. Alumina suspensions (70% wt.) and wheat flour (20–
30% vol.) were used to synthesize different particle sized porous alumina ceramics [401]. 
Hydroxyapatite/alumina composite based foam was synthesized via a precipitation method under a 
variety of pH values that showed a good concentration of Ca²⁺ and PO43- contents [402]. The chemical 
modification of porous alumina surface with vitronectin and peptide (i.e., arginine-glycine-aspartic 
acid cysteine (RGDC)) enhanced bone cell adhesion and production of extracellular matrix [403].  
Porous anodic alumina (PAA) can be fabricated on the surface of other materials through 
anodization process [404,405]. It can be considered a good nanocontainer to load active agents such 
as drugs or biomolecules [406]. Evaporation induced self-assembly derived mesoporous aluminum 
oxide was used for the delivery of poor-water soluble compound Telmisartan (anti-blood pressure 
drug) with 45% loading efficiency [407]. The drug is not loaded within the pores of the PAA 
completely, but the surface itself can hold some of this load, which can be quite high; this promotes 
another phase release [408,409].  
Calcium phosphate with 20% alumina (Ca3(PO4)2–Al2O3) bio-ceramic composite revealed 
enhanced biocompatibility and mechanical properties [410]. Using alumina nanowires reinforcement 
in polyhydroxy butyrate-chitosan (PHB-CTS/3% Al2O3) scaffolds enhanced the mechanical properties 
of the scaffold. The addition of alumina increased by ten times the tensile strength of PHB-CTS/3% 
Al2O3, which became higher than its counterpart for the original PHB-CTS scaffold [411].  
Al2O3 coating was used for improving the performance of stainless steel 316L and Ti-6Al-4V 
implants [412]. In general, coating materials are used to protect the surface of the implant material 
and the interface with the biological system at hand [413]. Nanorod-like HA-coated porous Al2O3 was 
fabricated by anodic oxidation that revealed excellent biological activity in vitro [414]. 
2.2.9. Copper 
Copper ions stimulate the proliferation of human vein endothelial cells and mesenchymal stem 
cells (MSCs) but not human dermal fibroblasts [415,416]. Copper nanoparticles can also act as 
antifungal and antibacterial agents [417]. Copper is commonly used in bone implants for its 
antimicrobial activity against a wide range of pathogens [418]. As copper is an essential component 
of the body, it may be more suitable for in vivo applications [25]. 
The importance of copper has been studied extensively because its deficiency can lead to 
osteoporosis [419]. Cu also stimulates angiogenesis and collagen deposition, which are key elements 
in wound healing [420]. The use of copper-based biomaterials is cost-effective compared to other vital 
materials based on gold and silver [421].  
Copper ions were incorporated into biologically active scaffolds for controlled release to 
improve vascular strengthening and antimicrobial action for prolonged periods [422]. Copper-doped 
wollastonite (Cu–Ws) particles (1184 nm) have shown biocompatibility towards mouse mesenchymal 
stem cells (mMSC) up to 0.05 mg/ml concentration [423]. A freeze-dried 
chitosan/hydroxyapatite/copper-zinc alloy (CS/nHAp/nCu–Zn) composite-based scaffold showed 
lower degradation and higher protein adsorption without producing toxicity towards rat 
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osteoprogenitor cells [422]. Collagen-copper-doped bioactive glass (CuBG-CS) scaffolds exhibited 
enhanced mechanical properties (up to 1.9-fold) and osteogenesis (up to 3.6-fold) than chitosan [424].  
Copper nanoparticles were investigated also for wound healing applications. 1 M 
concentration of 80 nm CuNPs was found not to be toxic to the cultured fibroblast, endothelial, and 
keratinocyte cells, and it supported endothelial cell migration and proliferation [425]. CuNPs may 
alter the structure of proteins and enzymes, affecting their normal functions and causing inactivation 
of bacterial functions at the injury site [426]. Chen et al. reported the cytotoxic effect of copper NPs 
towards human histolytic lymphoma (U937) and human cervical cancer cells by inducing apoptosis 
[427]. CuNPs were used to design a special drug delivery system for chemotherapy. For example, 
Figure 20 illustrates a mesoporous, upconversion, nanoparticles (mUCNPs)-based controlled-release 
drug carrier system exhibiting higher upconversion luminescence emission intensity [428]. 
 
Figure 20. Schematic illustration of the mUCNPs-based redox-stimuli responsive drug delivery 
system for tumor diagnosis and synergetic chemo-phototherapy (adapted with permission from 
Elsevier © 2020 [428]).  
2.2.10. Magnetic Nanoparticles 
Magnetic elements (i.e., iron, nickel, cobalt, and their oxides) were utilized for the fabrication of 
nanomaterials for different medical applications [429,430] such as MRI, drug delivery, medical 
diagnostics, cancer therapy, biosensoring, and magneto-optic devices. Magnetic nanoparticles can be 
synthesized through different techniques including co-precipitation [431], microemulsion [432], 
hydrothermal synthesis [433], sol–gel process [434], polyol synthesis [435], flow injection [436], 
sonolysis/sonochemical methods [437], microwave irradiation [438], electrochemical synthesis [439], 
solvothermal method [440], chemical vapor deposition [441], laser pyrolysis [442], and green 
synthesis [443] using biomass or biotemplate.  
Due to high magnetic flux density, magnetic nanoparticles were used for drug targeting [444] 
and bio-separation [445], including cell sorting [446]. Sun et al. [447] analyzed metallic, bi-metallic, 
magnetic cationic liposomes and superparamagnetic iron oxide nanoparticles for imaging and drug 
delivery. The surface of magnetic nanoparticles also needs to be functionalized to recognize specific 
targets (Figure 21) [448]. Polyethylene glycol (PEG) is one of the best polymers used for the 
functionalization of magnetic nanoparticles by surface modification [449]. Interestingly, surface 
modified magnetic nanoparticles reduce nonspecific interaction with biological molecules. 
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Figure 21. Surface modified magnetic nanoparticle. 
Magnetic manipulation is another important advantage of magnetic nanoparticles [450]. It is 
done by labeling cells with magnetic nanoparticles that can easily be controlled by remote control or 
external magnetic field [451]. The magnetic nanoparticles, which are usually smaller than 10 nm can 
be easily transported through skin lipid matrix and hair follicles to the stratum granulosum, where 
it is condensing between corneocytes [452].  
In orthopedic surgery, implant-associated infection is a serious issue, as stated in the previous 
sections. Infection around a bone graft can lead to serious illness or failure of surgery. Drug-loaded 
Fe3O4 composites promote cell adhesion, proliferation, and osteogenic differentiation of hBMSCs 
[453–455]. In stem cell therapy for bone regeneration, an application of these NPs is the magnetic 
targeting of stem cells to the deserved locations, known as magnetic homing of stem cells. For 
example, penetration of ferumoxide-labeled cells into porous hydroxyapatite ceramic implanted in a 
rabbit ulnar defect was significantly facilitated by this approach, which improved bone formation 
even in the chronic process [456]. 
2.2.11. Summary and Statistical Analysis of the Survey on Inorganic Nanobiomaterials  
The survey on inorganic nanobiomaterials presented in Section 2.2 covered some 230 articles, 
practically the same as its counterpart for organic biomaterials not counting about 30 articles on 
fabrication techniques of silica and magnetic nanoparticles. 
While the number of technical papers appears to be rather uniformly distributed among the ten 
types of inorganic nanomaterials considered in this survey, it should be noted that most studies 
focused on nanoparticles and their functionalization for drug/gene/therapy delivery, cell labeling, 
biosensing, and bioimaging (75%), followed by studies on development and fabrication of new 
composite materials and scaffolds (25%). 
Gold and titania present the largest variety of nanostructures and the latter material may also be 
available in the form of nanotubes. Gold nanoparticles may represent the best solution for most 
applications in view of the possibility of controlling size and dimensions of nanostructures as well as 
for their special physical properties (for example, local plasmon resonance). However, massive 
utilization of GNPs is obviously limited by the high cost of gold. Silica and titania nanoparticles also 
are widely utilized as standalone materials or in combination with gold and silver nanoparticles. 
Similar to what has been observed for organic nanobiomaterials, a rapidly growing research area 
in the field of inorganic nanobiomaterials for bone tissue engineering is to hybridize them with other 
materials (e.g., chitosan, PLA, PLGA, collagen, and hydroxyapatite) to enhance mechanical 
properties, biocompatibility and osteogenetic properties of the modified materials. Development of 
high-performance scaffolds comprised of multiple materials is the final stage of this complicated 
process. 
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3. Applications of Nanobiomaterials 
Nanobiomaterials have outstanding mechanical, chemical, electrical and optical properties, 
which make them highly suited for a variety of biological applications [70]. Nanotechnologies made 
it possible to develop new nanoscale materials (nanobiomaterials) with upgraded surface area to 
volume ratio, enabling more surface interactions [457–459]. As nanobiomaterials possess very specific 
properties that may be tailored to specific targets (i.e., solubility (for otherwise insoluble drugs), 
carriers for hydrophobic entities, multifunctional capability, active and passive targeting, ligands 
(size exclusion), and reduced toxicity), they have tremendous potential for disease identification (as 
imaging tools), care delivery, and prevention in new ways [107]. Nanobiomaterials are special kinds 
of materials that are introduced into the body for the treatment of damaged hard tissues [460]. The 
huge variety of biomedical applications of nanobiomaterials are illustrated in Figure 22 [428,461–463]. 
 
Figure 22. Applications of nanobiomaterials in the biomedical field. 
Nanobiomaterials have well-defined nanostructures such as size, shape, channels, pore 
structure, and surface domain [464]. Nanoscale dimension enables nanobiomaterials to develop 
critical physical and chemical characteristics that enhance their performance [465,466]. The properties 
and behaviors of nanobiomaterials, therefore, allow the diagnosis, monitoring, treatment, and 
prevention of diseases [467]. Nano-size materials show more catalytic reactions at their surface than 
macro-sized or conventional materials [468]. The nanoscale biomaterials create biomimetic feature 
towards most of the proteins which support further biological reactions such as cell attachment, 
growth, proliferation and generation of new tissue [36].  
3.1. Bone Regeneration 
A perfect bone and cartilage repair scaffold materials should neither suppress the activity of 
normal cells nor induce toxicity during and after implantation [469]. Figure 23 illustrates the basic 
cycle of tissue regeneration using nanobiomaterials or derived scaffolds [255].  
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Figure 23. Basic principle procedures for tissue engineering. (Adapted with permission from ©2019 
American Chemical Society [255]). 
The various synthetic nanostructured matrices are able to stimulate cell differentiation with a 
focus on preserving the structural features, composition, and biology of natural bone tissue [470]. The 
main constituents used so far in this regard are nano-hydroxyapatite [471], anodized titanium [472], 
collagen [473], and silver-incorporated calcium silicate. Nanobiomaterials (1–100 nm) generated from 
polymers, metals, ceramics, and composites act as effective constituents for hard tissue and play a 
significant role in osteointegration on nanostructured surfaces [474].  
Alumina has been widely used for the fabrication of knee and hip joint prosthesis with low wear 
rates [475]. Bioactive glasses were used as a prosthesis for the restoration of the ossicular chain of the 
middle ear and oral implant to preserve the alveolar ridge from bone resorption [476,477]. Different 
metal oxides such as ZnO, Fe2O3, TiO2, and Al2O3, and polymers such as PLA, PGA, and their 
copolymers were used with bioactive glass systems for hard tissue engineering applications [478,479]. 
3.2. Drug Delivery 
As mentioned above, various nanobiomaterials can be used for bone regeneration, prevention 
of infections, and osteointegration [480,481]. A nanoparticle that functions as carrier can stabilize the 
bioactive molecules through encapsulation [482], facilitating targeting cellular delivery and targeted 
drug release [483,484]. Nanospheres, tubes and capsules are widely accepted tools for targeted and 
sustained release drug delivery because of their small size and high specific surface area, which 
encapsulates the drug molecules and shows high reactivity to the surrounding tissues [485]. The 
materials selected for nanosphere fabrication depend on application principles and requirements. 
Some factors in this regard include size, drug characteristics, surface properties, biodegradability and 
biocompatibility of materials and drug release profile [486]. The 2D and 3D structures of scaffolds 
can be useful for the drug (poorly soluble drugs) loading purpose in tissue engineering (Figure 24).  
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Figure 24. Drugs and biomolecules loaded scaffold for tissue engineering. 
3.3. Gene Delivery 
The rapid development of nanotechnology made available novel DNA and RNA delivery 
systems for gene therapy (Figure 25) that can be used instead of viral vectors [487]. Gene therapy 
collectively refers to therapies aimed at manipulating gene expression in living organisms by 
supplying exogenous DNA or RNA that is incorporated or not incorporated to cure or prevent 
diseases [488]. There is great incentive to work towards safer and targeted viral vectors and to 
engineer more effective non-viral systems that can achieve secure, effective gene therapy in humans 
because of the enormous potential for gene therapies to influence medicine. 
 
Figure 25. Fundamental steps of gene delivery by nanocarriers (orange spheres). (Adapted with 
permission from ©2016 Royal Society of Chemistry [489]) 
There are a number of nanocarriers used for gene delivery (Figure 25) [489] applications which 
are based on lipids [490,491], liposomes [492–494], dendrimers [495], polymers [496,497], graphene 
[498,499], carbon nanotubes (CNTs) [500,501], mesoporous silica [502], gold nanoparticles [503,504], 
magnetic nanoparticles [505,506], and other types of inorganic nanoparticles.  
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The number of clinical trials for cancer [507], liver disease [508], hemophilia [509], and bone 
regeneration [510–512] is continuously increasing due to the promising opportunity to correct gene 
disorders. Nanomaterials are used for gene delivery because of their small size and superior stability 
[513]. Before the use of these nanomaterials, surfaces need to be functionalized with small 
biomolecules or polymers to adapt their physiochemical properties such as hydrophobicity, charge 
density, and binding affinity [514,515]. Factors including molecular weight, biodegradability, 
rigidity, charge density, pKa value, solubility, crystallinity, and hydrophobicity ensure effective and 
safe gene delivery [516,517].  
Surface-modified graphene oxide through cationic polymers such as polyethylenimine (PEI) 
provides a large surface area for the encapsulation of DNA molecules [518]. DNA/drug molecules 
attached graphene oxide conjugated provide an outstanding platform for the immobilization of 
nucleotides on its surface [519]. Mesoporous silica nanospheres (MSNs) and functionalized single-
walled carbon nanotubes (SWCNT) represent an excellent gene delivery system [520]. In Figure 26, a 
potential route is recorded for the use of dendrimers as vectors of gene delivery. As plasmid DNA 
penetrates the cell membrane, it makes (in vitro) a complex between dendrimer and DNA (called 
dendriplex). This complex is transported through the blood system to the specific cell. Finally, the 
DNA moves through the cytoplasm to reach the nucleus for gene expression in series [521,522]. 
 
Figure 26. Schematic diagram for a possible route in the use of dendrimers as gene delivery vectors. 
3.4. Anti-Infective Nanobiomaterials 
Disease, injury, and trauma can lead to serious bacterial infections, which cause disease and 
adverse complications in host tissues and even death of patients [523]. Nanobiomaterials made from 
polymers, metals, and ceramics might be a potential source of infection when they are introduced 
into the body [524,525]. Virus and bacterial infections cause unregulated damage that leads to organ 
failure [526]. In polymeric biomaterials, the most common bacterial infections are powered by 
Staphylococcus epidermidis (S. epidermidis) from skin and Staphylococcus aureus (S. aureus), which may 
identified on metallic biomaterials [527]. Ceramics and metals can represent an alternative because 
of their resistance to infection. However, in presence of minor imperfections on the surface or 
microfractures, pathogens, such as bacteria, can form a colony [528]. Biomaterials from natural 
sources were used as alternative as scaffolds for promoting regeneration but they carry a risk for 
pathogenic transmission [529].  
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3.5. Nanobiomaterials for Coating  
Micro/nanoscale tissue engineering scaffolds play a vital role on the organization of natural 
extracellular matrix [530]. Nanostructured 3D scaffolds enhance cell functioning, migration, 
differentiation, proliferation, and extracellular matrix formation [531].  
Nanobiomaterials used for coatings include silica (SiO2), titania (TiO2), zirconia (ZrO2), alumina 
(Al2O3), zinc oxide (ZnO), CNT, graphene, and various combined oxides [532]. Simple calcium 
phosphate coating method on metals, glasses, inorganic ceramics and organic polymers (such as 
PLGA, PS, PP, and silicone), collagens, and silk fibers can improve biocompatibility or enhance the 
bioreactivity for orthopedic applications [494,533]. TiO2 and Al2O3 can be used as biologically active 
coating agents, supporting cell adhesion, growth, osteogenic differentiation, bone matrix production, 
and mineralization [534]. Nanostructured TiO2 has a positive effect on the performance of bone cells. 
TiO2 is available in the form of nanocrystals [535], nanofibers [536], nanoparticles [537], also 
immobilized on nanotubes [538]. TiO2 nanotube coating on any substrate enhances hydroxyapatite 
formation in SBF [539]. Nano silica coating on Ti-6Al-4V alloys generates apatite and supports 
adhesion and attachment of human osteoblast-like Saos-2 cells [540]. Nitinol coated stainless steel has 
shown enhanced biocompatibility but Ni ions produce an allergic response and toxicity [541]. 
Zirconia coated pure and yttrium-stabilized nanostructure promote deposition of apatite from SBF, 
which supports cell adhesion and growth [542]. Zinc oxide doped with alumina or functionalized 
with the silane coupling agent KH550 supports the proliferation of fibroblasts [543]. 
Carbon nanotubes have been used with various synthetic and natural polymers or minerals for 
the improvement of mechanical properties [544]. CNT and other nano-carbon forms stimulate cell 
adhesion and growth of osteogenic cells. Graphene-based films and composites used for biomaterial 
coatings can be obtained from pure or oxidized graphene. These graphene-based films improve the 
osteogenic differentiation manifested by collagen I and osteocalcin, high calcium phosphate 
deposition, and high alkaline phosphatase activity [545,546]. Due to the antimicrobial impression of 
graphene, graphene oxide (GO), and their derivatives, these materials can be used for implant coating 
[547]. Graphene oxide (GO) coating on the collagen scaffold induces morphological changes 
depending on GO concentration [548]. The application of GO improved physical properties like 
compressive strength as well as adsorption of Ca and proteins without changing porosity [549]. 
Graphene oxide-silk fibroin (GO-SF) composite used as an alternative to coating with collagen, 
showed improved biomechanical properties and proved could work in cellular environments [550].  
HA can accelerate new bone formation by coating on titanium and tantalum scaffolds. It was 
demonstrated that after 6 weeks of implantation with titanium and tantalum scaffolds coated is 
possible to reach fully dense bone formation [551]. Calcium-phosphate-coated Fe foam showed better 
differentiation and proliferation rate of human mesenchymal stem cells than uncoated Fe foam [552]. 
Polymer-coated mesoporous silica nanoparticles are effective, cell-specific targeted 
chemotherapeutic agent delivery method [553]. In rat calvarial defects, HA-coated PLGA scaffolds 
alone promote bone regeneration and increased exposure to HA nanoparticles on the scaffold surface 
has been documented to result in accelerated bone deposition by local progenitors [554]. 
3.6. Nanostructured Scaffolds 
Scaffolds are artificial constructs that provide support, tensile strength, and aid in tissue 
ingrowth [555]. They can also serve as carriers for growth factors, drugs and other required 
ingredients [556]. Scaffolds mimic the presence of extracellular matrix and allow the replacement of 
tissue without producing any harmful disturbance with respect to surrounding tissues. An ideal 
scaffold should be biocompatible, biodegradable, bioactive, non-toxic, mechanically stable, 
biodegradable, and bioresorbable (Figure 27) [557]. The amalgamation of organic and inorganic 
materials with scaffolds may enhance morphology and mechanical properties, thus supporting better 
cell attachment and proliferation [558]. 
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Figure 27. Desired properties of an ideal scaffold. 
Scaffold properties can be improved by using nanoparticles because organic and inorganic 
minerals in natural bone have nanoscale structures [559]. Many studies found that the addition of 
titanium and iron improve biological and mechanical properties such as collagen synthesis and 
apatite generation [560,561]. In addition, engineered nanofibrous scaffolds are also suitable for 
loadbearing applications and can replace natural extracellular matrix (ECM) with artificial ECM. The 
nanofibrous scaffold can therefore get a much more suitable environment for cellular growth and 
eventual regeneration of the bone [562]. Nanofiber-based scaffolds have been fabricated by using 
different synthetic polymers including PCL [563–566], PLLA [567,568], copolymer [569], PLGA [61], 
and chitosan [569].  
Different kinds of metallic nanoparticles can be used for the synthesis of composite-based 
scaffolds with enhanced mechanical characteristics, cell adhesion, and bone tissue generating 
capacity [12]. The incorporation of titanium, iron, and alumoxane in a scaffold can improve 
mechanical properties, collagen synthesis, calcium deposition, and alkaline phosphatase activity 
[561].  
Graphene and its derivatives were used as reinforcement material for fibrous scaffolds, films, 
and hydrogels [570]. The graphene and graphene oxide incorporation into hydrogels yield 
enhancements in mechanical properties without producing adverse effects on encapsulated fibroblast 
cells [571]. Carbon-based nanomaterials can be used to improve mechanical strength of scaffolds 
[572]. Alumina, titania, bioglass, and hydroxyapatite support osteoblast adhesion and growth [573].  
Nanobiomaterial-based composite structures are an efficient platform for the synthesis of 
engineered scaffolds and application in bone tissue engineering (Figure 28) [574]. Nanocomposite-
based scaffolds exhibit inherent characteristics such as porous and rough surface and increased 
wettability, which promote fast bone regeneration. These nanocomposite-based scaffolds provide a 
porous structure for nutrients exchange and increased protein adsorption. Scaffolds exhibited 
micro/nano-scaled porous structural pathway for cell–scaffold interaction and integrin-triggered 
signaling pathway. The nanoscale features support bone cells (osteoblast) and bone-derived stem 
cells proliferation, migration, cell signaling, stem cell fate, and genetic cell fate. The nanobiomaterials 
based scaffold have notable mechanical and biological advantages and can induce bone tissue 
regeneration [531]. The nanostructured materials improve morphological characteristics of scaffolds 
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that may enhance osteoinduction, bone cell attachment, differentiation, proliferation, and natural 
bone cell growth within the extracellular matrix [12].  
Hydroxyapatite (HA) has attracted attention because of its inherent biological compatibility and 
bone conduction as well as its similarity with bone minerals [575]. For this reason, HA was combined 
with a number of synthetic and natural polymers such as polycaprolactone [576], poly (lactic acid) 
(PLA) [577], polyethylene, poly(lactic-co-glycolic acid) (PLGA) [203], collagen [578], gelatin [148], and 
chitosan [579] to fabricate scaffolds. These composite based scaffolds showed improved mechanical 
properties, porosity and biocompatibility without or with significantly less adverse effects. 
 
Figure 28. Engineered organic and inorganic nanobiomaterials for hard tissue engineering 
applications. 
3.7. Bone Cancer Therapy 
Cancer is the uncontrolled growth of tissues that could lead to invasion into other organs 
without proper regulation or differentiation [580]. Conventional cancer therapy is associated with 
multiple adverse side effects [581]. Bone metastases or “bone mets” occur when cancer cells from the 
primary tumor relocate to the bone and also spread in the prostate, breast, and lung, which leads to 
painful (75% of patients) and devastating skeletal-related events (SREs) [582,583]. Depending on the 
stage of the disease, history, and the overall health of the patient, disease management includes a 
combination of therapies as shown in Figure 29 [584]. 
 
Figure 29. Bone metastasis management through combination of therapies. 
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The different types of nanoparticles (NPs) used as carriers for small-molecule drugs, proteins, 
and nucleic acids [585] can be localized to specific disease locations for the treatment of bone 
metastasis [586]. Nanoparticles also improve the efficiency of other methods used for treating bone 
metastasis [587]. The effectiveness of NPs depends on their accumulation in vascularized solid 
tumors via the enhanced permeability and retention (EPR) effect [588]. A wide variety of 
nanomaterials have been developed in the 1 to 100 nm range and include various anti-tumor drugs 
(Figure 30) by fine-tuning the chemical structure, scale, and shape (morphology) that can regulate the 
nanomaterials' functionality [589]. 
 
Figure 30. Schematic representation of different types of nanomaterials and their drug-loaded 
conjugates employed in cancer therapy. (Adapted with permission from ©2019 Springer [589]) 
4. Counter-Indications 
There is inevitably some sort of interaction between the organic or inorganic materials and the 
biological environment when individual or composite biomaterials are put in contact with the tissues 
and fluids of the human body. The basic clinical research may decide that the materials should not 
cause any local or systemic adverse reactions. Recent studies exposed that nanosized materials can 
easily penetrate biological membranes of normal cells and enter vascular system to facilitate 
redistribution in different tissues. Nanomaterials, which by themselves are not very harmful, could 
become toxic if are ingested in higher concentration. The toxicity of metal based biomaterials to the 
liver is an important basis for the safety assessment of nanosized materials. Metal based nanoparticles 
release ions which may enter the cells and affect the functions of organelles, leading to liver injury. 
Various factors including amount, composition, pH, and fabrication techniques may decide the 
compatibility and cytotoxicity of biomaterials. The research is ongoing to improve the existing 
technologies which may produce highly compatible substitutes without producing adverse effects. 
5. Conclusions 
This review article provided a broad overview of the various types of organic and inorganic 
nanobiomaterials and their applications in the field of hard tissue engineering. Besides classifying 
nanobiomaterials, the survey covered several key aspects like bone/cartilage regeneration, drug/gene 
delivery, anti-infection properties, coatings, scaffold fabrication, and cancer therapy. A total of 550 
articles selected by means of web search engines widely used in science and engineering were 
reviewed in this study. Interestingly, the number of reviewed articles was approximately the same 
for organic and inorganic biomaterials. 
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Biomaterials science is a highly multidisciplinary area. Developments in life science and 
nanotechnology enabled scientists and engineers to conceive new designs and improve the existing 
bone structure. For example, advances in nanotechnology allowed for the development of novel 
methods for fabricating new nanostructured scaffolds possessing a higher efficiency in tissue 
regeneration. 
Nanomaterials represent an excellent tool for research and therapeutic approaches in bone tissue 
engineering. Organic nanomaterials are more biocompatible, nontoxic, and help more with cell 
regeneration than inorganic nanomaterials. However, inorganic nanomaterials provide better 
mechanical strength and inertness to chemical agent. From the references cited in this survey it 
appears that nanoparticles, graphene and nanocomposites are the most diffused types of 
nanostructures used for hard tissue applications. An important research trend which results in a 
rapidly growing number of published articles is the development of new composite nanobiomaterials 
especially for scaffold applications. 
Interactions between bone cells and nanomaterials depend on the composition of nanoparticles. 
Proper selection of nanoparticles may result in faster bone regeneration and recovery. Besides 
composition, the overall performance of a nanobiomaterial depends on porosity, microstructure, 
mechanical properties and functionality. Nanomaterials-based scaffolds also play a major role in 
three-dimensional tissue growth. Nanostructural modifications provide a favorable environment for 
bone regeneration.  
The survey presented in the article proved that tissue engineering supports (i) application of 
engineering design methods to functionally engineered tissues, (ii) development of novel 
biomaterials for constructing scaffolds that mimic extracellular matrix, and (iii) creating artificial 
microenvironments. Nanobiomaterials represent an excellent tool for research and therapeutic 
approaches in bone tissue engineering. However, further investigations should be aimed at 
producing advanced nanobiomaterials suitable for hard tissue engineering that can fill the gap 
between biomaterial fabrication and clinical implementation. 
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